Merck's immuno-oncology star wins fast U.K. nod; Aeterna Zentaris raises $37M;

@FierceBiotech: From @FiercePharmAsia: Glaxo plants a flag in Singapore with CEO Witty on hand. More | Follow @FierceBiotech

@JohnCFierce: ICYMI: Amgen is canning 300 Onyx staffers, abandoning campus in latest biopharma purge. News | Follow @JohnCFierce

@DamianFierce: $PTX is buying the rights to $ZGNX's opioid Zohydro ER for $100M up front and up to $283.5M more. Release | FiercePharma story | Follow @DamianFierce

> Merck's ($MRK) PD-1-blocking immunotherapy Keytruda won an early U.K. approval, becoming the first treatment to take advantage of a new accelerated review process in the country. News

> Zogenix ($ZGNX) sold off the rights to its controversial painkiller Zohydro to Pernix Therapeutics ($PTX) for $100 million up front and up to $283.5 million in milestones. More

> Aeterna Zentaris ($AEZS) raised $37 million in a stock offering, money earmarked for its pipeline of cancer treatments. Release

Medical Device News

@FierceMedDev: J&J hosts developer of novel skin cancer diagnostic at its new life science incubator. FierceDiagnostics article | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Texas Medical Center adds 20+ device companies to its incubator. Story | Follow @VarunSaxena2

@EmilyWFierce: Get this week's edition of FierceDiagnostics, feat. OpGen's superbug Dx, new coverage decisions for $EXAS and more. Newsletter | Follow @EmilyWFierce

> Med tech moves in on Georgia: Varian, MiMedix to expand with up to 250 new jobs. Story

> J&J's DePuy Synthes recalls orthopedic surgical tool, but not ready to replace. News

> Olympus asked FDA to loosen its belt on cleaning guidelines for endoscope devices. Article

Pharma News

@FiercePharma: Stats, surprises and secrets revealed in annual drug-spending report. Story | Follow @FiercePharma

@EricPFierce: #FDA finds sends a warning letter to a second Novacyl API plant for retesting failed batches. News | Follow @EricPFierce

@CarlyHFierce: UPDATED: Just where does AbbVie expect to find $7B in Imbruvica sales? Article | Follow @CarlyHFierce

> Merck's Keytruda snags inaugural approval in U.K.'s early-access scheme. Story

> J&J pleads guilty, pays $20M fine tied to metal-tainted Children's Tylenol. News

Drug Delivery News

> Zohydro changes hands as Zogenix sells to Pernix for $100M-plus. More

> J&J partner Halozyme joins daratumumab trials with delivery tech in tow. Story

> Irish research center wins EU funding to study and develop transdermal delivery methods. News

> Will the third licensee of a buccal tablet for mouth fungus succeed where others have failed? More

> Developer of injectable osteoarthritis treatment postpones $75M IPO, raises $4M in debt instead. Article

Diagnostics News

> Philips, UC Irvine collaborate on diagnosing breast cancer among women with dense breasts. Story

> Exact Sciences signs on Anthem and Aetna to noninvasive colon cancer Dx. Report

> Quest and Personalis dive into exome sequencing for rare pediatric neurological disorders. Editor's corner

> J&J hosts developer of novel skin cancer diagnostic at its new life science incubator in Silicon Valley. More

> Navidea joins forces with Norgine to market cancer imaging Dx in EU. Article

Pharma Marketing News

> Lipitor keeps on selling, so Pfizer will keep on producing it in Ireland. Item

> Just where does AbbVie expect to find $7B in Imbruvica sales? Story

> Stats, surprises and secrets revealed in annual drug-spending report. More

> Onyx field reps spared in Amgen's 300-job bloodletting. Article

> Bayer puts cancer-fighting country crooner onstage to promote colonoscopies. Report

Suggested Articles

When thinking about clinical research patient recruitment, a crucial step is building effective patient recruitment advertising campaigns.

Novavax delayed the start of a large phase 3 trial for its COVID-19 vaccine in the U.S. and Mexico, thanks to delays in scaling up manufacturing.

The decision to dump IL33r antagonist GSK3772847 follows lackluster clinical data on rival candidates against the same target.